ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its Calquence can work in newly diagnosed chronic lymphocytic leukemia (CLL).